Colorectal cancer tumors lacking the homologous recombination repair factor RAD51D exhibit increased programmed death ligand-1 expression and altered immune responses, according to findings published in Nature. Researchers found that this DNA repair deficiency drives genomic instability, activates interferon-related signaling through the JAK-STAT axis, and increases tumor sensitivity to PD-L1 blockade therapies.
Genomic Instability Triggers Interferon Signaling Axes
Defects in homologous recombination repair serve as a primary engine for genomic instability in malignancies. Yet, how specific repair components dictate immune checkpoint expression in colorectal cancer has remained poorly understood.
Transcriptomic data show that losing RAD51D causes DNA damage to accumulate inside tumor cells. This cellular stress triggers cGAS-STING-related pathways, which in turn dial up interferon-related signaling. Specifically, the JAK1-STAT1-IRF1 cascade experiences a significant boost, driving higher transcription and surface presentation of PD-L1.
When researchers tested pharmacological RAD51 inhibition, the treatment recapitulated these exact molecular features. Disrupting repair functions mimics the genetic deficiency, setting off the same downstream immune alterations.
CD8+ T-Cell Exhaustion and Immune Dependencies in Vivo
Under untreated conditions, RAD51D-deficient tumors grow faster than their repair-proficient counterparts. This accelerated expansion relies heavily on immune-dependent mechanisms.
Tumors missing RAD51D show a reduced abundance of CD8+ T-cells in vivo. The infiltrating T-cells display impaired effector activity alongside heightened exhaustion profiles. Genetic silencing or pharmacological inhibition of STAT1 successfully attenuates the upregulation of PD-L1, identifying STAT1 as a necessary mediator of this phenotype.
To confirm the role of adaptive immunity, researchers tracked tumor growth in Rag1-/- mice and following deliberate CD8+ T-cell depletion. In both scenarios, the growth advantage associated with RAD51D deficiency vanished entirely. Adaptive immunity and functioning CD8+ T-cells dictate whether these deficient tumors thrive or stall.
Therapeutic Vulnerabilities to Checkpoint Blockade
Despite fostering an immunosuppressive environment before treatment, RAD51D-deficient tumors reveal a distinct therapeutic vulnerability. They exhibit a markedly higher sensitivity to PD-L1 blockade.
Administering checkpoint inhibitors to models with RAD51D-deficient cancers reverses the baseline immune suppression. Treated subjects experience renewed CD8+ T-cell infiltration, restored effector activity, and a measurable reduction in T-cell exhaustion. These results connect homologous recombination repair defects directly to checkpoint regulation outcomes in colorectal cancer, offering a potential rationale for patient stratification in future immunotherapy trials.
